BIOCON.BOBIOCON.BOBSE
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank95
3Y CAGR+377.1%
5Y CAGR+248.1%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+377.1%/yr
vs -4.3%/yr prior
5Y CAGR
+248.1%/yr
Recent acceleration
Acceleration
+381.4pp
Accelerating
Percentile
P95
Near historical high
vs 5Y Ago
511x
Strong expansion
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 1986.36% |
| Q3 2025 | -138.15% |
| Q2 2025 | -96.96% |
| Q1 2025 | 3234.31% |
| Q4 2024 | -23.20% |
| Q3 2024 | 38.32% |
| Q2 2024 | -97.43% |
| Q1 2024 | 95892.31% |
| Q4 2023 | -66.67% |
| Q3 2023 | -20.41% |
| Q2 2023 | -99.71% |
| Q1 2023 | 1391.78% |
| Q4 2022 | 18.29% |
| Q3 2022 | -47.27% |
| Q2 2022 | -85.58% |
| Q1 2022 | 831.90% |
| Q4 2021 | 50.11% |
| Q3 2021 | 10.97% |
| Q2 2021 | -89.93% |
| Q1 2021 | 812.70% |
| Q4 2020 | 3.89% |
| Q3 2020 | 7.74% |
| Q2 2020 | -82.08% |
| Q1 2020 | 404.94% |
| Q4 2019 | 6.09% |
| Q3 2019 | 21.09% |
| Q2 2019 | -89.73% |
| Q1 2019 | 971.27% |
| Q4 2018 | -25.96% |
| Q3 2018 | 34.19% |
| Q2 2018 | -42.38% |
| Q1 2018 | 14.23% |
| Q4 2017 | 1.18% |
| Q3 2017 | -2.62% |
| Q2 2017 | -81.73% |
| Q1 2017 | 1281.00% |
| Q4 2016 | -14.45% |
| Q3 2016 | 33.03% |
| Q2 2016 | -74.62% |
| Q1 2016 | 44.18% |